
News|Articles|April 1, 2010
Formulary Digital Edition April 2010
Reducing cardiovascular risk is patients with type 2 diabetes: management of dyslipidemia; Focus on naproxicond; Drug Watch: Agents in late-stage development for the treatment of hepatitis C
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA issues third rejection of bevacizumab to treat wet AMD
2
Predictions for 2026 from Lucille Accetta, RPh, M.P.H., MBA, A.J. Loiacono and Allan Pannier, Pharm.D. MBA
3
Predictions for 2026 from Marci Chodroff, M.D., Jeffrey Casberg, RPh, M.S., and others
4
Predictions for 2026 from Tracy Baroni Allmon, Sharon Faust, Mike Kolodij, and others
5





















































